WCN25-4036 Improved Outcomes with an Additional Rituximab Dose in Primary Membranous Nephropathy

Results:The number of patients in the age group of 31-50 were highest in the study.The M:F ratio was around 3:1. 95 patients were PLA2R positive at the baseline(74.8%).40.6% of PLA2R negative patients required no IS while only 22.1% PLA2R positive patients continued without IS.The highest mean 24 hour urine protein and creatinine levels at baseline were seen in MP group and baseline albumin levels were lowest in MP group.After 6 months of treatment the PLA2R negative patients became 68.5%.68.8% patients achieved remission(CR+PR) across the PLA2R negative groups at 6 months while 63.1% in PLA2R positive groups.87patients who completed 1 year of different treatments, 47 (54%) were in remission at 1 year while 7 achieved remission after change in their treatment.At 1 year, 54.1% maintained remission in PLA2R negative groups while 53.9% maintained remission in PLA2R positive group in same duration.Highest number of major and minor adverse events were seen in MP group followed by rituximab group.Conclusions: 74.8% study population were PLA2R positive at the baseline.40.6% of PLA2R negative patients required no IS while only 22.1% PLA2R positive patients could continue without IS.After 6 months of treatment the PLA2R levels became negative in 68.5% across all the groups which was 73.7% at one year.Comparable number of patients achieved and maintained remission in both arms at 6 months and 1 year.Overall, serological remission preceded the proteinuric remission.A long term follow up of will help us to know the persistence of remission and other outcomes in this population I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.